Rallybio Corp
RLYB
查看詳細走勢圖
0.785USD
+0.007+0.93%
收盤 12/19, 16:00（美東）報價延遲15分鐘
32.92M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+0.93%
5天
+7.24%
1月
+28.69%
6月
+156.12%
今年開始到現在
-18.23%
1年
-17.37%
查看詳細走勢圖
TradingKey Rallybio Corp股票評分
單位: USD 更新時間: 2025-12-19操作建議
Rallybio Corp當前公司基本面數據相對非常健康，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名171/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為持有。最高目標價1.00。中期看，股價處於上升通道。近一個月，市場表現很強，技術面和基本面綜合得分較高，很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Rallybio Corp評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
4
分析師
持有
評級
1.000
目標均價
+47.19%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Rallybio Corp亮點
亮點風險
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
業績增長期
公司處於發展階段，最新年度總收入636.00K美元
估值低估
公司最新PE估值-2.50，處於3年歷史低位
機構減倉
最新機構持股29.20M股，環比減少17.38%
先鋒集團持倉
明星投資者先鋒集團持倉，最新持倉999.63K股
活躍度降低
近期活躍度降低，過去20天平均換手率-0.43
Rallybio Corp新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Rallybio Corp簡介
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
公司代碼RLYB
公司Rallybio Corp
CEOUden (Stephen)
網址https://rallybio.com/
常見問題
Rallybio Corp(RLYB)的當前股價是多少？
Rallybio Corp(RLYB)的當前股價是 0.785。
Rallybio Corp 的股票代碼是什麼？
Rallybio Corp的股票代碼是RLYB。
Rallybio Corp股票的52週最高點是多少？
Rallybio Corp股票的52週最高點是1.080。
Rallybio Corp股票的52週最低點是多少？
Rallybio Corp股票的52週最低點是0.220。
Rallybio Corp的市值是多少？
Rallybio Corp的市值是32.92M。
Rallybio Corp的淨利潤是多少？
Rallybio Corp的淨利潤為-57.77M。
現在Rallybio Corp(RLYB)的股票是買入、持有還是賣出？
根據分析師評級，Rallybio Corp(RLYB)的總體評級為持有，目標價格為1.000。
Rallybio Corp(RLYB)股票的每股收益（EPS TTM）是多少
Rallybio Corp(RLYB)股票的每股收益（EPS TTM）是-0.314。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
